More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Carfilzomib [PR-171] [868540-17-4]
Chemical Structure
Chemical Structure
Chemical Structure

Carfilzomib [PR-171] [868540-17-4]

Research Use Only
AG-CR1-3669
AdipoGen Life Sciences
Estimated Purity>98%
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Molecular Weight719.9
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Carfilzomib [PR-171] [868540-17-4]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger,Non-hazardous
  • Molecular Formula
    C40H57N5O7
  • Molecular Weight
    719.9
  • Scientific Description
    Chemical. CAS: 868540-17-4. Formula: C40H57N5O7. MW: 719.9. Synthetic. Potent and irreversible second-generation peptide epoxyketone class proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=5.2nM) and the beta5i subunit [LMP7] of the 20S immunoproteasome (IC50=14nM), with minimal crossreactivity to other proteases. Displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome compared to bortezomib. Anticancer compound effective against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma, and various solid tumors (IC50s=2.4-20nM). - Potent and irreversible second-generation peptide epoxyketone class proteasome inhibitor. Synthetic analog of the microbial product epoxomicin (Prod. No. AG-CN2-0422). Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=5.2nM) and the beta5i subunit [LMP7] of the 20S immunoproteasome (IC50=14nM), with minimal cross-reactivity to other proteases. Displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome compared to bortezomib (Prod. No. AG-CR1-3602). Anticancer compound effective against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma and various solid tumors (IC50s=2.4-20nM).
  • SMILES
    O=C([C@]1(C)OC1)[C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC(C)C)NC([C@H](CCC3=CC=CC=C3)NC(CN4CCOCC4)=O)=O)=O)=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome: S.D. Demo, et al.; Cancer Res. 67, 6383 (2007)
  • Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma: D.J. Kuhn, et al.; Blood 110, 3281 (2007)
  • The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells: C. Stapnes, et al.; Br. J. Haematol. 136, 814 (2007)
  • Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome: F. Parlati, et al.; Blood 114, 3439 (2009)
  • Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs): D.J. Kuhn, et al.; Curr. Cancer Drug Targets 11, 285 (2011) (Review)
  • Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia: A. Sacco, et al.; Clin. Cancer Res. 17, 1753 (2011)
  • Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events: S. Arastu-Kapur, et al.; Clin. Cancer Res. 17, 2734 (2011)
  • Carfilzomib: a novel second-generation proteasome inhibitor: M.L. Khan & A.K. Stewart; Future Oncol. 7, 607 (2011)
  • The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4: Y. Zang, et al.; Autophagy 8, 1873 (2012)
  • From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes: K.B. Kim & C.M. Crews; Nat. Prod. Rep. 30, 600 (2013)